acute coronary syndrome - anti-anginal drugs - all type of patients clinical trials results meta-analysis

<h1> <a href="TM16-88-anti-anginal drugs-acute coronary syndrome" > <strong>acute coronary syndrome</strong> - anti-anginal drugs </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t5738.htm"> MERLIN TIMI 36, 2007 </a> <br> NCT00099788 </td> <td> ranolazine 1000 mg twice daily for the duration of the trial (intitialy 200 mg intravenously for 1 hour, followed by an 80 mg/h intravenous infusion)<br>  <i>versus</i> <br> placebo </td> <td> Hospitalized with NSTE-ACS; ischemic symptoms at rest within 48 hours; and at least one indicator of moderate to high risk, defined as elevated troponin or creatine kinase-myocardial band, ST-depression >0.1 mV, diabetes, or TIMI risk score for unstable angina/NSTEMI >=3 </td> <td> follow-up median 11.4 months<br> n=3279/3281<br> Parallel groups<br> Double blind <br> 17 countries </td> </tr> </table> <h2>References</h2> <p> <b>MERLIN TIMI 36, 2007 : </b> Morrow DEvaluation of a novel anti-ischemic agent in acute coronary syndromes: the primary results of the metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndrome (MERLIN)-TIMI 26 trial <i>American College of Cardiology Annual Scientific Session, New Orleans, LA, March 2007</i> [PMID ] </p> <p> <b>MERLIN TIMI 36, 2007 : </b> Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald EEffects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. <i>JAMA 2007 Apr 25;297:1775-83</i> [PMID 17456819] </p>